Affiliation:
1. Australian Army Malaria Institute, Brisbane.
Abstract
The in vitro activities of the new biguanide PS-15 and its putative active metabolite, WR99210, were determined against seven different isolates or clones of Plasmodium falciparum. The mean 50% inhibitory concentrations of PS-15 and WR99210 were 1,015 and 0.06 ng/ml, respectively. WR99210 was up to 363 times more potent than cycloguanil, the active metabolite of proguanil, against cycloguanil-resistant parasites. The pronounced activity of WR99210 against multidrug-resistant P. falciparum indicates that further studies are required to determine the value of the prodrug, PS-15, as an antimalarial agent.
Publisher
American Society for Microbiology
Subject
Infectious Diseases,Pharmacology (medical),Pharmacology
Reference17 articles.
1. Canfield C. J. 1986. New antimalarials under development p. 99-100. In L. J. Bruce-Chwatt (ed.) Chemotherapy of malaria 2nd ed. World Health Organization Monograph Series no. 27. World Health Organization Geneva Switzerland.
2. PS-15: a potent, orally active antimalarial from a new class of folic acid antagonists;Canfield C. J.;Am. J. Trop. Med. Hyg.,1993
3. Analogues of N-benzyloxydihydrotriazine: in vitro antimalarial activity against Plasmodium falciparum;Childs G. E.;Ann. Trop. Med. Parasitol.,1986
4. Management of malaria with special reference to drug resistance;Harinasuta T.;Jpn. J. Trop. Med. Hyg.,1988
5. Anti-Pneumocystis carinii activity of PS-15, a new biguanide folate antagonist;Hughes W. T.;Antimicrob. Agents Chemother.,1993
Cited by
19 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献